Application of DDO-2728 in preparation of medicine for treating plateau encephaledema
DDO-2728 inhibits abnormal mitochondrial division of astrocytes and reduces membrane potential, improves the adaptability of cells to hypoxic environment, solves the problem of treatment of plateau cerebral edema, significantly alleviates the symptoms of plateau cerebral edema, and provides low oxygen to plateau An effective treatment plan for inducing plateau cerebral edema.
Patent Information
- Application Number
- CN202411245018.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art treatment measures for plateau cerebral edema are limited, especially in the low oxygen environment of plateau. There is a lack of effective drugs to inhibit abnormal division of astrocyte mitochondria and reduce membrane potential, resulting in worsening of cerebral edema and patients face serious consequences.
DDO-2728 is used as a drug to reduce the mitochondrial potential by inhibiting the abnormal division of mitochondria in astrocytes, and improve the adaptability of cells to the hypoxic environment, thereby reducing plateau brain edema. DDO-2728 can be used alone or in combination with other drugs, and the dosage forms include granules, tablets, etc., and the administration method is oral or injection.
Effectively inhibit the abnormal division of mitochondria in astrocytes in hypoxic environments, reduce membrane potential, improve backup respiratory capacity, improve mitochondrial function, and significantly reduce the symptoms of plateau cerebral edema, providing an effective treatment plan for plateau hypoxia-induced plateau cerebral edema.
Smart Images

Figure CN118986991A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine and relates to application of DDO-2728 in preparing a medicine for treating high altitude cerebral edema. Background Art
[0002] High-altitude cerebral edema is a serious disease caused by the hypoxic environment of the plateau. It is characterized by an increase in water content in brain cells, which leads to an increase in brain tissue volume and is accompanied by increased intracranial pressure. High-altitude cerebral edema develops rapidly and progresses rapidly. If it is not treated in time, patients often suffer from serious sequelae, and even progress to coma and death, posing a threat to the life and health of troops and tourists stationed in high-altitude areas. Due to the limited understanding of the pathogenesis of high-altitude cerebral edema, there are currently limited effective measures to deal with high-altitude cerebral edema, but prevention is still the main focus. Timely oxygen inhalation, rapid reduction of altitude and auxiliary drug treatment are of positive significance for the treatment of high-altitude cerebral edema. In clinical practice, active treatments such as hypertonic glucose, mannitol, adrenal glucocorticoids, and cytochrome C are mainly used to reduce brain edema, reduce brain cell metabolism, and provide energy to promote recovery. However, human bodies vary greatly, and the only means are not enough to overcome the problems brought about by high-altitude cerebral edema. Summary of the invention
[0003] The present invention provides an application of DDO-2728 in preparing a medicine for treating high altitude cerebral edema.
[0004] In the first aspect of the present invention, the present invention provides the use of DDO-2728 in the preparation of a drug for treating high altitude cerebral edema, wherein the molecular formula of DDO-2728 is C 28 H 17 F 3 N 4 O 7 , the chemical structure is shown below:
[0005]
[0006] Among them, the high-altitude cerebral edema is the increase in brain water content when exposed to a low-pressure and low-oxygen environment at high altitude.
[0007] Furthermore, the high altitude cerebral edema includes cerebral edema induced during acute high altitude exposure or chronic high altitude exposure.
[0008] Furthermore, the drug is a drug that reduces high-altitude cerebral edema by inhibiting the abnormal fission of astrocyte mitochondria caused by low pressure and hypoxia at high altitude.
[0009] In a second aspect of the present invention, the present invention provides the use of DDO-2728 in the preparation of a drug for inhibiting abnormal fission of astrocyte mitochondria, wherein the abnormal fission of astrocyte mitochondria is caused by high-altitude hypoxia and low pressure.
[0010] In the third aspect of the present invention, the present invention provides the use of DDO-2728 in the preparation of a drug for reducing the mitochondrial membrane potential of astrocytes.
[0011] In the fourth aspect of the present invention, the present invention provides the use of DDO-2728 in the preparation of a drug for improving the spare respiratory capacity of astrocytes under a low-pressure and low-oxygen environment at high altitude.
[0012] Furthermore, in the above application, the drug is DDO-2728 used alone or DDO-2728 used in combination with other drugs.
[0013] Furthermore, in the above application, the dosage form of the drug is one of granules, tablets, granules, pills, capsules, sustained-release agents, pellets and injections.
[0014] Furthermore, in the above application, the drug is administered orally or by injection.
[0015] Compared with the prior art, the present invention utilizes DDO-2728 to inhibit the abnormal fission of astrocyte mitochondria under the high-altitude hypoxic environment, reduce the mitochondrial membrane potential of astrocytes, improve the spare respiratory capacity of astrocytes under the high-altitude low-pressure and low-oxygen environment, improve mitochondrial function, and improve the adaptability of astrocytes to the high-altitude low-pressure and low-oxygen environment, thereby having a good therapeutic effect on high-altitude cerebral edema induced by high-altitude low-pressure and low-oxygen environment, and is of great significance for the development of drugs for treating high-altitude cerebral edema induced by high-altitude low-pressure and low-oxygen environment. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The figure is a comparison of the m6A modification levels in the cerebral cortex of mice in the control group, model group and treatment group; Figure A is an RNAdot blot showing the m6A expression abundance in the cortex of each group of mice; Figure B is a statistical chart of the m6A expression abundance in each group;
[0017] Figure 2 Figure 1 is a comparison of the degree of brain edema in mice in the control group, model group, and treatment group; Figure A is a diagram of brain edema in mice in each group; Figure B is a statistical comparison of brain water content in mice in each group;
[0018] Figure 3 The figure is a comparison of the mitochondrial fission of astrocytes in the control group, model group and treatment group of mice; Figure A is the fission of mitochondrial astrocytes in each group under a microscope; Figure B is a statistical diagram of the degree of mitochondrial fission in each group;
[0019] Figure 4 This is a comparison of the changes in mitochondrial membrane potential of astrocytes in mice in the control group, model group, and treatment group;
[0020] Figure 5 Statistical graph of the spare respiratory capacity of mitochondria in astrocytes of mice in the control group, model group and treatment group. DETAILED DESCRIPTION
[0021] In order to more clearly illustrate the present invention, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the content specifically described below is illustrative and non-restrictive and should not be used to limit the scope of protection of the present invention. The experimental methods without specifying specific conditions in the embodiments are usually carried out according to conventional conditions or according to the conditions recommended by the manufacturer.
[0022] The DDO-2728 used in the present invention has a CAS number of 3029515-97-4, a molecular formula of C28H17F3N4O7, a molecular weight of 578.45, and was purchased from MCE Company with a product number of HY-155489.
[0023] Unless otherwise noted, all reagents used in the examples of the present invention can be obtained from sales companies.
[0024] Example 1: Experiment on increasing m6A modification level in mouse cerebral cortex under hypobaric and hypoxic exposure by DDO-2728
[0025] (1) Control group (NN): 3 28 g male adult mice.
[0026] (2) Model group (HH): 3 male adult mice weighing 28 g were exposed to a hypobaric hypoxic chamber simulating an altitude of 7000 m for 48 h.
[0027] (3) Treatment group (HH+DDO-2728): Three 28 g male adult mice were intraperitoneally injected with 10 mg / kg DDO-2728 every two days for four days, and then exposed to a hypobaric hypoxic chamber at a simulated altitude of 7000 m for 48 hours.
[0028] After the above experiment, the mice were perfused through the heart to remove systemic blood, and the mouse cerebral cortex was quickly peeled off. The tissue was placed in TRIzol for homogenization and RNA was extracted. After heating 10μl (1ug) RNA at 95 degrees Celsius for 2 minutes to open the secondary structure, it was spotted on the NC membrane, fixed by UV crosslinking for 30 minutes, blocked with 5% milk for one hour, and then hybridized with m6A antibody, washed, and autoradiographed. The presence or absence of spots or the depth of color represent the level of m6A modification. Figure 1It can be seen that the m6A modification level in the model group was significantly reduced, and in the treatment group, the m6A modification level was significantly increased compared with the model group. Therefore, it is proved that DDO-2728 can effectively inhibit the downregulation of m6A modification level induced by hypobaric hypoxia.
[0029] Example 2: Experiment on the effect of DDO-2728 on alleviating brain edema in mice in a high altitude cerebral edema model induced by hypobaric hypoxia exposure:
[0030] (1) Control group (NN): 3 28 g male adult mice.
[0031] (2) Model group (HH): 3 male adult mice weighing 28 g were exposed to a hypobaric hypoxic chamber simulating an altitude of 7000 m for 48 h.
[0032] (3) Treatment group (HH+DDO-2728): Three 28 g male adult mice were intraperitoneally injected with 10 mg / kg DDO-2728 every two days for four days, and then exposed to a hypobaric hypoxic chamber at a simulated altitude of 7000 m for 48 hours.
[0033] After the above experiment, the mouse cerebral cortex was quickly peeled off, numbered and weighed. The brain was dried in a muffle furnace at 100 degrees Celsius for 72 hours. After the balance weight was determined, the weight of the dried brain stem was weighed. The calculation formula of brain water content is: brain water content = (wet weight - dry weight) / wet weight * 100%. Figure 2 It can be seen that the brain water content in the model group increased significantly, which is consistent with the characteristics of the high-altitude cerebral edema model. In the treatment group, the brain water content decreased significantly compared with the model group. Therefore, it is proved that DDO-2728 can effectively improve the symptoms of high-altitude cerebral edema induced by hypobaric hypoxia.
[0034] Example 3: DDO-2728 inhibits the imbalance of mitochondrial fission and fusion induced by hypoxia.
[0035] (1) Control group (Nor): primary cultured mouse astrocytes.
[0036] (2) Model group (Hyp): primary cultured mouse astrocytes were exposed to 1% O2 for 24 h.
[0037] (3) Treatment group (Hyp+DDO-2728): Primary cultured mouse astrocytes were exposed to 5 μM DDO-2728 combined with 1% O2 for 24 hours.
[0038] After the above experiment, Tomm20 was used to label mitochondria, and a Leia SP8 laser confocal microscope was used to image the mitochondrial network morphology and reflect the mitochondrial fission and fusion. Figure 3It can be seen that the mitochondrial branch length of astrocytes in the model group became shorter, and the mitochondrial network structure was obviously fragmented, indicating that mitochondrial fission intensified. The branch length of mitochondria in the treatment group was significantly longer than that in the model group, abnormal fission was inhibited, fragmentation was significantly improved, and the mitochondrial network structure returned to normal. This shows that DDO-2728 can effectively inhibit hypoxia-induced mitochondrial fission and alleviate the damage of hypoxia to astrocyte mitochondria. DDO-2728 can slow down the damage of high-altitude cerebral edema by improving mitochondrial function.
[0039] Example 4: DDO-2728 improves the effect of hypoxia on mitochondrial membrane potential of astrocytes.
[0040] (1) Control group (Nor): primary cultured mouse astrocytes.
[0041] (2) Model group (Hyp): primary cultured mouse astrocytes were exposed to 1% O2 for 24 h.
[0042] (3) Treatment group (Hyp+DDO-2728): Primary cultured mouse astrocytes were exposed to 5 μM DDO-2728 combined with 1% O2 for 24 hours.
[0043] After the above experiment, a commonly used fluorescent probe JC-1 was used to observe the changes in mitochondrial membrane potential using a Leia SP8 laser confocal microscope. Changes in mitochondrial membrane potential are an important indicator of cell function status, which reflects the activity and health of mitochondria. For example, a decrease in mitochondrial membrane potential is a landmark event in the early stage of cell apoptosis. A decrease in membrane potential may also indicate impaired cellular energy metabolism. Changes in mitochondrial membrane potential are also related to oxidative stress, because excessive production of ROS can damage mitochondrial function and lead to a decrease in membrane potential. In addition, changes in mitochondrial membrane potential can reflect the metabolic state of cells. JC-1 dye is a cationic lipid fluorescent dye that is widely used as an indicator for detecting mitochondrial transmembrane potential (ΔΨm). This method reflects the level of mitochondrial membrane potential by changes in the fluorescence color of JC-1. When the mitochondrial membrane potential is high, JC-1 aggregates in the mitochondrial matrix to form polymers (JC-1Aggregates) and produce red (or orange) fluorescence. When the mitochondrial membrane potential decreases, JC-1 cannot aggregate in the mitochondrial matrix and exists in the form of monomers (JC-1Monomers), producing green fluorescence. Therefore, by observing the change in fluorescence color, the change in mitochondrial membrane potential can be easily detected. Figure 4It can be seen that the green fluorescence intensity of astrocytes in the model group was significantly enhanced after hypoxia treatment, indicating that the mitochondrial membrane potential decreased, while the green fluorescence intensity of astrocytes in the treatment group was weakened, indicating that the depolarization of the mitochondrial membrane potential was improved. This shows that DDO-2728 can maintain the mitochondrial membrane potential under hypoxia, thereby maintaining the normal function of mitochondria and reducing the damage to cells caused by high-altitude cerebral edema.
[0044] Example 5: DDO-2728 enhances the spare respiratory capacity of astrocyte mitochondria under hypoxia.
[0045] (1) Control group (Nor): primary cultured mouse astrocytes.
[0046] (2) Model group (Hyp): primary cultured mouse astrocytes were exposed to 1% O2 for 24 h.
[0047] (3) Treatment group (Hyp+DDO-2728): Primary cultured mouse astrocytes were exposed to 5 μM DDO-2728 combined with 1% O2 for 24 hours.
[0048] After the above experiments, the Agilent Seahorse Cell Mitochondrial Stress Test Kit is used to evaluate mitochondrial function. The spare respiratory capacity index is often used to evaluate the ability of cells to cope with energy metabolism challenges when undergoing activation, differentiation and / or proliferation and facing stress environments. Through these measurements, in-depth analysis of the cell's bioenergetic status, mitochondrial health, and potential metabolic disorders can be performed. Figure 5 It can be seen that the spare respiratory capacity of astrocytes in the model group was significantly reduced, while DDO-2728 in the treatment group can significantly improve the spare respiratory capacity of astrocyte mitochondria. This shows that DDO-2728 can significantly improve the ability of mitochondria to cope with the increased energy demand caused by hypoxia, thereby improving the adaptability of astrocytes and reducing cell apoptosis during brain edema.
[0049] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Use of DDO-2728 in the preparation of a drug for treating high altitude cerebral edema, wherein the molecular formula of DDO-2728 is C 28 H 17 F 3 N 4 O 7 , the chemical structure is shown below: in, The high altitude cerebral edema is the increase in brain water content when exposed to a low pressure and low oxygen environment at high altitude.
2. The use according to claim 1, It is characterized in that The high altitude cerebral edema includes cerebral edema induced during acute high altitude exposure or chronic high altitude exposure.
3. The use according to claim 1, It is characterized in that The drug is a drug for alleviating high-altitude cerebral edema by inhibiting abnormal fission of astrocyte mitochondria caused by low pressure and hypoxia at high altitude.
4. Use of DDO-2728 in the preparation of a drug for inhibiting abnormal fission of astrocyte mitochondria, wherein the abnormal fission of astrocyte mitochondria is caused by high-altitude hypoxia and low pressure.
5. Application of DDO-2728 in the preparation of drugs for reducing mitochondrial membrane potential of astrocytes.
6. Application of DDO-2728 in the preparation of drugs for improving the spare respiratory capacity of astrocytes in high-altitude low-pressure and low-oxygen environments.
7. The use according to any one of claims 1 to 6, It is characterized in that The drug is DDO-2728 used alone or DDO-2728 used in combination with other drugs.
8. The use according to any one of claims 1 to 6, It is characterized in that The dosage form of the medicine is one of granules, tablets, granules, pills, capsules, sustained-release preparations, dripping pills and injections.
9. The use according to any one of claims 1 to 6, It is characterized in that The drug is administered orally or by injection.
